EVALUATION OF SEROLOGICAL METHODS IN THE DIAGNOSIS OF CHLAMYDIA-PNEUMONIAE PNEUMONIA DURING AN EPIDEMIC IN FINLAND

被引:92
作者
EKMAN, MR
LEINONEN, M
SYRJALA, H
LINNANMAKI, E
KUJALA, P
SAIKKU, P
机构
[1] NATL PUBL HLTH INST,SF-00300 HELSINKI,FINLAND
[2] UNIV HELSINKI,DEPT VIROL,SF-00100 HELSINKI 10,FINLAND
[3] NATL PUBL HLTH INST,OULU,FINLAND
[4] UNIV OULU,CENT HOSP,SF-90220 OULU 22,FINLAND
关键词
D O I
10.1007/BF02098463
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A complement fixation (CF) test, a micro-immunofluorescence (micro-IF) test and an enzyme immunoassay (EIA) using Re-lipopolysaccharide as antigen were compared in the diagnosis of chlamydial infection in 136 mainly elderly patients hospitalized with community-acquired pneumonia during a Chlamydia pneumoniae epidemic in Finland in 1986-1987. Chlamydial pneumonia was diagnosed in 58 (42.6 %) of the 136 pneumonia patients; 44 (75.9 %) of them could be shown by micro-IF to be caused by Chlamydia pneumoniae, three by Chlamydia psittaci and four by Chlamydia spp. Only 5 (11.4 %) of 44 patients with Chlamydia pneumoniae pneumonia were IgM-positive, indicating that the majority of cases were reinfections. In this population of mainly elderly patients the CF test was insensitive, being positive in only 6 (10.3 %) of 58 cases of chlamydial pneumonia. The EIA detected 72.4 % of cases and micro-IF 87.9 % of cases (including infections with Chlamydia pneumoniae, Chlamydia psittaci and Chlamydia spp.). In the EIA 77 % of positive cases were positive in serum samples taken a week apart, whereas the corresponding figure for micro-IF was 50 %. In micro-IF the measurement of IgA antibody levels is recommended and IgM-positive sera should be retested after removal of IgG antibody to avoid false-positive findings due to presence of rheumatoid factor. The collection of a third serum sample, for instance one month after onset, is also recommended, since half of the patients showed a diagnostic response in the micro-IF only in the sera taken one month apart.
引用
收藏
页码:756 / 760
页数:5
相关论文
共 19 条
[1]   USE OF HL CELLS FOR IMPROVED ISOLATION AND PASSAGE OF CHLAMYDIA-PNEUMONIAE [J].
CLES, LD ;
STAMM, WE .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (05) :938-940
[2]   AN EPIDEMIC OF INFECTIONS DUE TO CHLAMYDIA-PNEUMONIAE IN MILITARY CONSCRIPTS [J].
EKMAN, MR ;
GRAYSTON, JT ;
VISAKORPI, R ;
KLEEMOLA, M ;
KUO, CC ;
SAIKKU, P .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (03) :420-425
[3]   NEW AND EMERGING ETIOLOGIES FOR COMMUNITY-ACQUIRED PNEUMONIA WITH IMPLICATIONS FOR THERAPY - A PROSPECTIVE MULTICENTER STUDY OF 359 CASES [J].
FANG, GD ;
FINE, M ;
ORLOFF, J ;
ARISUMI, D ;
YU, VL ;
KAPOOR, W ;
GRAYSTON, JT ;
WANG, SP ;
KOHLER, R ;
MUDER, RR ;
YEE, YC ;
RIHS, JD ;
VICKERS, RM .
MEDICINE, 1990, 69 (05) :307-316
[4]   A NEW CHLAMYDIA-PSITTACI STRAIN, TWAR, ISOLATED IN ACUTE RESPIRATORY-TRACT INFECTIONS [J].
GRAYSTON, JT ;
KUO, CC ;
WANG, SP ;
ALTMAN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (03) :161-168
[5]   A NEW RESPIRATORY-TRACT PATHOGEN - CHLAMYDIA-PNEUMONIAE STRAIN TWAR [J].
GRAYSTON, JT ;
CAMPBELL, LA ;
KUO, CC ;
MORDHORST, CH ;
SAIKKU, P ;
THOM, DH ;
WANG, SP .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (04) :618-625
[6]  
JOKINEN C, 1991, 51991 U KUOP ORG REP
[7]   THE ETIOLOGY OF PNEUMONIA - APPLICATION OF BACTERIAL SEROLOGY AND BASIC LABORATORY METHODS [J].
KERTTULA, Y ;
LEINONEN, M ;
KOSKELA, M ;
MAKELA, PH .
JOURNAL OF INFECTION, 1987, 14 (01) :21-30
[8]   EPIDEMICS OF PNEUMONIA CAUSED BY TWAR, A NEW CHLAMYDIA ORGANISM, IN MILITARY TRAINEES IN FINLAND [J].
KLEEMOLA, M ;
SAIKKU, P ;
VISAKORPI, R ;
WANG, SP ;
GRAYSTON, JT .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (02) :230-236
[9]   COMPARISON OF ELISA AND RIA FOR MEASUREMENT OF PNEUMOCOCCAL ANTIBODIES BEFORE AND AFTER VACCINATION WITH 14-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE [J].
KOSKELA, M ;
LEINONEN, M .
JOURNAL OF CLINICAL PATHOLOGY, 1981, 34 (01) :93-98
[10]   A SENSITIVE CELL-LINE, HL CELLS, FOR ISOLATION AND PROPAGATION OF CHLAMYDIA-PNEUMONIAE STRAIN TWAR [J].
KUO, CC ;
GRAYSTON, JT .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (03) :755-758